Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Piaget's Stage 3 of Cognitive Development01:17

Piaget's Stage 3 of Cognitive Development

1.1K
During Piaget's concrete operational stage, from ages 7 to 11, children exhibit a marked increase in logical thinking skills, specifically in relation to tangible, real-world events. This stage is characterized by the development of several essential cognitive concepts, including conservation, reversibility, and classification, all of which support the child's evolving capacity for structured thought.
Conservation and Constancy of Quantity
A significant cognitive milestone in the...
1.1K
Piaget's Stage 1 of Cognitive Development01:14

Piaget's Stage 1 of Cognitive Development

1.7K
The sensorimotor stage, the initial phase of Jean Piaget's theory of cognitive development, spans the first two years of a child's life. During this period, infants actively engage with their surroundings, building cognitive awareness through direct interaction with the world. This interaction is primarily based on sensory perception and motor actions, allowing infants to gradually understand basic physical properties and predict how objects interact within their environment.
Exploration...
1.7K
Piaget's Stage 2 of Cognitive Development01:14

Piaget's Stage 2 of Cognitive Development

914
The preoperational stage, the second of Jean Piaget's four stages of cognitive development, spans approximately ages 2 to 7 and is characterized by the emergence of symbolic thinking. During this stage, children use language, images, and symbols to represent objects and concepts, enabling them to engage in imaginative and pretend play. This symbolic thinking supports children's ability to perform make-believe actions, such as imagining a broom as a horse or their hand as a phone, blending...
914
Piaget's Stage 4 of Cognitive Development01:19

Piaget's Stage 4 of Cognitive Development

631
The formal operational stage, as described in Piaget's cognitive development theory, begins around age 11 and extends into adulthood. It marks the emergence of advanced cognitive abilities that differentiate adolescent and adult thinking from those of younger children. This stage is characterized by abstract reasoning, hypothetical-deductive reasoning, and a more complex understanding of self and others.
Abstract Reasoning and Hypothetical-Deductive Thinking
Unlike the concrete operational...
631
Stages of Infection01:26

Stages of Infection

65.2K
Stages of infection describe what happens to a susceptible host once a pathogen invades the human body. The stages of infection are incubation, prodromal, illness, stage of decline, and convalescence. The incubation stage is the period from exposure to a pathogen until symptoms start. The infected person is unaware of impending illness as the pathogens grow and multiply within the body. The duration may vary depending on the type of infection. The incubation period of measles averages ten to...
65.2K
Multiple Allele Traits01:49

Multiple Allele Traits

38.1K
The Concept of Multiple Allelism
38.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatotoxicity With Elevated Bilirubin Secondary to Prophylactic Doses of Unfractionated Heparin: A Case Report and Review of Heparin-Induced Hepatotoxicity.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians·2021
Same author

Emerging Therapies for Patients With Difficult-to-Treat Migraine.

P & T : a peer-reviewed journal for formulary management·2018
Same author

Risk Reduction to Disease Management: Clinical Pharmacists as Cardiovascular Care Providers.

Current problems in cardiology·2018
Same author

Old and New Drug Classes Expanding To Include Glaucoma Treatments.

P & T : a peer-reviewed journal for formulary management·2018
Same author

Targeting Remission in Moderate-to-Severe Crohn's Disease.

P & T : a peer-reviewed journal for formulary management·2018
Same author

The role of the pharmacist in hypertension management.

Current opinion in cardiology·2018
Same journal

Formulary Substitution of Proton Pump Inhibitors Based on Acquisition Price: Changes in Usage and Costs of Acid-Suppressant Therapies.

P & T : a peer-reviewed journal for formulary management·2021
Same journal

Is Ciprofloxacin in Combination With Beta-lactam Antibiotics a Recipe for Thrombocytosis?: A Case Report of Thrombocytosis in a Patient Receiving Ciprofloxacin and Ceftriaxone.

P & T : a peer-reviewed journal for formulary management·2021
Same journal

Looking for Trouble: Identifying and Treating Hypotension.

P & T : a peer-reviewed journal for formulary management·2019
Same journal

Research Briefs.

P & T : a peer-reviewed journal for formulary management·2019
Same journal

The Impact of Self-Monitoring Blood Glucose Adherence On Glycemic Goal Attainment in an Indigent Population, With Pharmacy Assistance.

P & T : a peer-reviewed journal for formulary management·2019
Same journal

Continuous Glucose Monitoring: A Review of Available Systems.

P & T : a peer-reviewed journal for formulary management·2019
See all related articles

Related Experiment Video

Updated: Jan 31, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.0K

Promising Multiple Sclerosis Agents In Late-Stage Development.

Troy Kish

    P & T : a Peer-Reviewed Journal for Formulary Management
    |December 19, 2018
    PubMed
    Summary
    This summary is machine-generated.

    New multiple sclerosis (MS) drugs in late-stage development aim for better safety and affordability. These advancements offer hope for improved patient outcomes and more accessible treatments.

    More Related Videos

    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
    11:35

    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

    Published on: June 30, 2014

    58.8K
    A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
    08:18

    A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

    Published on: December 26, 2015

    18.1K

    Related Experiment Videos

    Last Updated: Jan 31, 2026

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    12.0K
    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
    11:35

    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

    Published on: June 30, 2014

    58.8K
    A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
    08:18

    A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

    Published on: December 26, 2015

    18.1K

    Area of Science:

    • Neurology
    • Pharmacology
    • Drug Development

    Background:

    • Multiple sclerosis (MS) treatment requires drugs with improved safety profiles.
    • Enhancing treatment affordability is crucial for patient access and adherence.
    • Current therapeutic options may present challenges in terms of side effects or cost.

    Purpose of the Study:

    • To review emerging pharmaceutical agents for multiple sclerosis (MS) currently in late-stage development.
    • To highlight new drugs that may offer enhanced safety profiles.
    • To discuss advancements that could improve the affordability of MS treatments.

    Main Methods:

    • Literature review of late-stage clinical trial data.
    • Analysis of safety and efficacy data for novel MS agents.
    • Assessment of potential cost-effectiveness and market accessibility.

    Main Results:

    • Several promising new drug candidates for MS are nearing completion of clinical trials.
    • These agents demonstrate potential for improved tolerability compared to existing therapies.
    • Early indications suggest some new treatments may offer more affordable options for patients.

    Conclusions:

    • Late-stage development holds significant promise for new multiple sclerosis (MS) therapies.
    • Future MS treatment landscapes may include safer and more cost-effective options.
    • These advancements are critical for improving the long-term management and quality of life for individuals with MS.